Indications for: ADACEL
Tetanus, diphtheria, and pertussis active booster immunization in persons 10–64 years of age. Immunization during the 3rd trimester of pregnancy to prevent pertussis in infants <2 months of age.
Adults and Children:
<10yrs or ≥65yrs: not recommended. 10–64yrs: 0.5mL IM once. Routine booster: give 1st dose ≥5yrs after last DTaP or Td dose. A 2nd Adacel dose may be given ≥8yrs after 1st Tdap dose. Immunization during pregnancy: give Adacel during the 3rd trimester. Wound management: may give booster dose at ≥5yrs after last tetanus toxoid-containing vaccine.
Anaphylaxis associated with any previous diptheria, tetanus, pertussis vaccine. Encephalopathy within 7 days after previous pertussis-containing vaccine.
Progressive or unstable neurologic disorders. Guillain-Barre syndrome (within 6 weeks) of previous tetanus vaccination. Previous Arthus-type hypersensitivity reaction: not recommended until ≥10yrs after prior dose of tetanus toxoid-containing vaccine. Immunodeficiency. Risk of syncope. Have epinephrine inj (1:1000) available. Latex allergy (prefilled syringes). Pregnancy. Nursing mothers.
Concomitant vaccines: see full labeling. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.
Inj site reactions, headache, body ache or muscle weakness, tiredness, chills, fever, GI upset, myalgia, malaise.
Register pregnant patients exposed to Adacel by calling (800) 822-2463.
Generic Drug Availability:
Single-dose vials—5, 10; Single-dose prefilled syringes—5